

Edgar Filing: SCHERING PLOUGH CORP - Form 425

SCHERING PLOUGH CORP
Form 425
March 09, 2009

Filed by Schering-Plough Corporation
Pursuant to Rule 425 under the Securities Act of 1933
and deemed filed pursuant to Rule 14a-12
of the Securities Exchange Act of 1934, as amended

Subject Company: Schering-Plough Corporation
(Commission File No. 001-06571)

The following fact sheet was made available on-line on March 9, 2009.

MERCK AND SCHERING-PLOUGH TO COMBINE

**Combined Company Positioned for Sustainable Growth Through Scientific Innovation
and a Stronger, More Diversified Product Portfolio**

Description	Merck & Co., Inc. is a global research-driven pharmaceutical company dedicated to putting patients first. Established in 1891, Merck discovers, develops, manufactures and markets vaccines and medicines to address unmet medical needs. The Company devotes extensive efforts to increase access to medicines through far-reaching programs that not only donate Merck medicines but help deliver them to the people who need them. Merck also publishes unbiased health information as a not-for-profit service.	Schering-Plough is an innovation-driven, science-centered global health care company. Through its own biopharmaceutical research and collaborations with partners, Schering-Plough creates therapies that help save and improve lives around the world. The company applies its research-and-development platform to human prescription, animal health and consumer health care products. Schering-Plough's vision is to Earn Trust, Every Day with the doctors, patients, customers and other stakeholders served by its colleagues around the world.
Website	www.merck.com	www.schering-plough.com
Employees	55,200	51,000
2008 Revenues	\$23.9 billion	\$18.5 billion
2008 Revenue by Geographic Region	United States - \$13,371 million Europe, Middle East and Africa - \$5,774 million Japan - \$1,824 million Other - \$2,883 million	United States - \$5,556 million Europe and Canada - \$8,903 million Latin America - \$1,987 million Asia Pacific - \$2,056 million

Edgar Filing: SCHERING PLOUGH CORP - Form 425

2008 R&D Investment	\$4.8 billion	\$3.5 billion
Headquarters	Whitehouse Station, New Jersey	Kenilworth, New Jersey
Cash and investments (as of 12/31/08)	\$12 billion	\$3.5 billion
Major pharmaceutical and vaccine products	<p>Singulair (montelukast sodium)</p> <p>Zetia (ezetimibe) and Vytorin (ezetimibe/simvastatin)</p> <p>Cozaar (losartan potassium) and Hyzaar (losartan potassium and hydrochlorothiazide)</p> <p>Gardasil (human papillomavirus (HPV) quadrivalent (types 6, 11, 16, 18) vaccine, recombinant)</p> <p>Januvia (sitagliptin) and Janumet (sitagliptin/metformin hydrochloride)</p>	<p>Zetia (ezetimibe) and Vytorin (ezetimibe/simvastatin)</p> <p>Remicade (infliximab)</p> <p>Nasonex (mometasone furoate monohydrate)</p> <p>Temodar (temozolomide)</p> <p>PEG-Intron (peginterferon alfa-2b)</p>

Edgar Filing: SCHERING PLOUGH CORP - Form 425

Novel products in late stage development

CV: MK-0859 (anacetrapib), MK-7418 (rolofylline), MK-524 A and B (extended-release niacin/laropiprant and extended-release niacin/laropiprant/simvastatin)
Oncology: MK-8669 (deforolimus)
Neuroscience: MK-0974 (telcagepant)
Women's Health: MK-0822 (odanacatib) and V-503

CV: SCH-530348 (thrombin receptor antagonist) and acadesine
Immunology: Simponi (golimumab)
Infectious Diseases: vicriviroc and boceprevir
Women's Health: corifollitropin alfa, esmirtazapine and NOMAC/E2
Neuroscience: Saphris (asenapine), Bridion (sugammadex)
Respiratory: mometasone/formoterol, grass pollen immunotherapy tablet

Business segments

Prescription
Vaccine
Animal Health joint venture (Merial)
Consumer Health joint venture (J&J-Merck)

Prescription
Animal Health
Consumer Health (OTC)

Executive Management Teams

Richard T. Clark, chairman, president and chief executive officer

Willie A. Deese, executive vice president and president, Merck Manufacturing Division

Kenneth C. Frazier, executive vice president and president, Global Human Health

Mirian Graddick-Weir, executive vice president, Human Resources

Peter N. Kellogg, executive vice president and chief financial officer

Peter S. Kim, Ph.D., executive vice president and president, Merck Research Laboratories

Bruce N. Kuhlik, executive vice president and general counsel

J. Chris Scalet, executive vice president, Global Services, and chief information officer

Fred Hassan, chairman and chief executive officer

Robert J. Bertolini, executive vice president and chief financial officer

Richard S. Bowles III, senior vice president, Global Quality Operations

C. Ron Cheeley, senior vice president, Global Human Resources

Carrie S. Cox, executive vice president and president, Global Pharmaceuticals

Thomas P. Koestler, executive vice president and president, Schering-Plough Research Institute

Raul E. Kohan, senior vice president and president, Global Animal Health

Ian McInnes, senior vice president and president, Global Supply Chain

Lori Queisser, senior vice president, Global Compliance and Business Practices

Thomas J. Sabatino, Jr., executive vice president and general counsel

Brent Saunders, senior vice president and president, Consumer Health Care

###

Forward-Looking Statements

This communication contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements are based on both Merck's and Schering-Plough's managements current expectations and involve risks and uncertainties, which may cause results to differ materially from those set forth in the statements. The forward-looking statements may include statements regarding product development, product potential or financial performance. No forward-looking statement can be guaranteed, and actual results may differ materially from those projected. Merck and Schering-Plough undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Forward-looking statements in this communication should be evaluated together with the many uncertainties that affect either companies' business, particularly those mentioned in the risk factors and cautionary statements set forth in Item 1A of either companies' 10-K for the year ended December 31, 2008, and in their periodic reports on Form 10-Q and Form 8-K, which the companies incorporate by reference.

These reports are available at www.merck.com and www.schering-plough.com.

Additional Information

In connection with the proposed transaction, Schering-Plough will file a registration statement, including a joint proxy statement of Merck and Schering-Plough, with the Securities and Exchange Commission (the SEC). Investors are urged to read the registration statement and joint proxy statement (including all amendments and supplements to it) because they will contain important information. Investors may obtain free copies of the registration statement and joint proxy statement when they become available, as well as other filings containing information about Merck and Schering-Plough, without charge, at the SEC's Internet site (www.sec.gov). These documents may also be obtained for free from Schering-Plough's Investor Relations web site (www.schering-plough.com) or by directing a request to Schering-Plough Investor Relations at (908) 298-7436. Copies of Merck's filings may be obtained for free from Merck's Investor Relations web site (www.merck.com) or by directing a request to Merck's Office of the Secretary at (908) 423-1000.

Merck and Schering-Plough and their respective directors and executive officers and other members of management and employees are potential participants in the solicitation of proxies from Merck and Schering-Plough shareholders in respect of the proposed transaction.

Information regarding Schering-Plough's directors and executive officers is available in Schering-Plough's proxy statement for its 2008 annual meeting of shareholders, filed with the SEC on April 23, 2008, and information regarding Merck's directors and executive officers is available in Merck's preliminary proxy statement for its 2009 annual meeting of stockholders, filed with the SEC on February 25, 2009. Additional information regarding the interests of such potential participants in the proposed transaction will be included in the registration and joint proxy statement filed with the SEC in connection with the proposed transaction.

###
